Xiaopeng Yu

Suggest Changes
Learn More
BACKGROUND The addition of bevacizumab (BEV) to cytotoxic chemotherapy regimens (CTX) was believed to be effective; however, its magnitude of benefits is still controversial. So a meta-analysis and(More)